PazopanibPDGFRATargeted therapyTemozolomidePleomorphic liposarcoma (PLPS) is a heterogeneous resistant group of tumors. Complete surgical resection is the only known way to treat PLPS. PLPS is reristant to both radiation and chemotherapy. Therefore, precise individualized therapy is needed to improve ...
pazopanib has shown a median PFS of 4.6 months in the PALETTE trial24. On the other hand, patients with the poorest prognosis could benefit more from well-planned palliative and supportive care than chemotherapy. In this retrospective analysis of patients with L-sarcoma treated with trabectedin in...
Women who achieve a response to initial adjuvant chemotherapy may be candidates for maintenance therapy, with the goal of inducing a lasting remission or prolonging the disease-free interval before recurrence. The rationale for maintenance therapy is to delay disease progression by eliminating residual,...
Such a ratio would not reflect absolute circulating endothelial cell numbers in blood samples because of inclusion of leukocytes, which are strongly influenced by infections or cancer therapies, including chemotherapy or radiation. Therefore, accurate assessment of the number of circulating endothelial ...
Renal cell carcinoma is often treated by surgery and targeted therapy (Chung et al, 2003; Gustafsson et al, 2009a) as it is relatively resistant to standard radiation therapy and cytotoxic chemotherapy (Deschavanne and Fertil, 1996; Ku et al, 2014). Increasing attention has been drawn to ...
chemotherapy and radiation, and hence a major goal in sarcoma research has been to develop molecular targetted therapies.30–32 Our observations that TBX3 expression is elevated in sarcoma cell lines and patient-derived tissue sections repre- sentative of both simple (synovial sarcoma) and complex...
Treatment choice is influenced by a large number of factors [1], and careful consideration is required to strike a balance between the benefits of treatment and the associated side effects. Table 1 Preferred chemotherapy and endocrine agents and regimens for HER2-negative metastatic breast cancer ...
The US National Cancer Institute defines chemotherapy as a treatment relying on killing cancer cells or inhibiting the process of cell division (mitosis). However, the currently available treatments used in a clinical setting are ineffective and cures are relatively rare [6]. Most patients treated ...
Immune cells, such as tumor associated macrophages (TAMs), can affect the response of tumor cells to chemotherapy through a process called environment-mediated drug resistance. A study by Amit et al. showed that TAMs can secrete the enzyme cytidine deaminase which metabolizes gemcitabine into its ...
Antibody-drug conjugates (ADCs) are an emerging class of targeted therapeutics having an improved therapeutic index over traditional chemotherapy. Drugs and linkers have been the focus of ADC development, in addition to (monoclonal) antibody (mAb) and target selection. Recently, however, the importanc...